KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Capital Expenditures (2016 - 2026)

Neogenomics filings provide 17 years of Capital Expenditures readings, the most recent being $5.0 million for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 11.11% to $5.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.2 million, a 3132.88% increase, with the full-year FY2025 number at $1.7 million, up 69.37% from a year prior.
  • Capital Expenditures hit $5.0 million in Q1 2026 for Neogenomics, up from -$17.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $16.2 million in Q2 2023 to a low of -$28.4 million in Q4 2024.
  • Median Capital Expenditures over the past 5 years was $5.6 million (2024), compared with a mean of $589647.1.
  • The widest YoY moves for Capital Expenditures: up 375.72% in 2024, down 109323.08% in 2024.
  • Neogenomics' Capital Expenditures stood at -$24.7 million in 2022, then skyrocketed by 99.89% to -$26000.0 in 2023, then plummeted by 109323.08% to -$28.4 million in 2024, then soared by 38.76% to -$17.4 million in 2025, then soared by 128.7% to $5.0 million in 2026.
  • The last three reported values for Capital Expenditures were $5.0 million (Q1 2026), -$17.4 million (Q4 2025), and $8.3 million (Q3 2025) per Business Quant data.